In this multi-center study of 233 adults undergoing reduced-intensity conditioning HCT for primary myelofibrosis, five-year survival was 47% and donor type was the only independent factor associated with survival. Researchers analyzed outcomes data submitted to CIBMTR from 83 transplant centers. Median age of patients was 55 years. Risk stratification according to DIPSS: low, 12%; intermediate-1, 49%; intermediate-2, 37%; and high, 1%. Adjusted five-year survival for matched sibling donor, well-matched unrelated donor (URD), and partially matched/mismatched URD were 56%, 48%, and 34%, respectively (p=0.002). The authors conclude that this therapy is a potentially curative option with donor type influencing survival.
Gupta V, et al. Biol Blood Marrow Transplant
Reduced-Intensity HCT for Primary Myelofibrosis is Potentially Curative
Nov 2013